Vinpocetine, cognition, and epilepsy. Epilepsy & behavior : E&B Meador, K. J., Leeman-Markowski, B., Medina, A. E., Illamola, S. M., Seliger, J., Novak, G., Lin, C., Ivanisevic, M., Razavi, B., Marino, S., Boyd, A., Loring, D. W. 2021; 119: 107988


OBJECTIVE: Vinpocetine has been shown to enhance memory in animal models, with possible cognitive benefit in humans. The present study sought to demonstrate if vinpocetine can enhance cognition in healthy volunteers or patients with epilepsy. In addition, we compare blood levels of vinpocetine and its active metabolite (apovincaminic acid; AVA) in humans and animals to further characterize factors related to possible therapeutic benefit.METHODS: The cognitive effects of vinpocetine were assessed in healthy adult volunteers (n?=?8) using a double-blind, randomized, crossover design at single doses (placebo, 10, 20, and 60?mg oral). Cognitive effects of vinpocetine in patients with focal epilepsy (n?=?8) were tested using a double-blind, randomized, crossover design at single doses (placebo, 20?mg oral) followed by one-month open label at 20?mg oral three times a day. The neuropsychological battery included both computerized and non-computerized tests. Levels of vinpocetine and AVA in the human studies were compared to levels in 45 mice across time dosed at 5-20?mg/kg intraperitoneal of vinpocetine.RESULTS: No significant cognitive benefits were seen in healthy volunteers or patients with epilepsy. No appreciable side effects occurred. Vinpocetine and AVA levels were lower in humans than animals.CONCLUSIONS: Vinpocetine was well tolerated, but was not associated with positive cognitive effects. However, blood levels obtained in humans were substantially less than levels in animals obtained from dosages known to be effective in one model. This suggests that higher dosages are needed in humans to assess vinpocetine's cognitive efficacy.

View details for DOI 10.1016/j.yebeh.2021.107988

View details for PubMedID 33957389